CRIS Current Research Information System

STEFANINI, BERNARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.905
NA - Nord America 739
EU - Europa 598
SA - Sud America 123
AF - Africa 55
OC - Oceania 2
Totale 3.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 708
CN - Cina 690
SG - Singapore 624
IT - Italia 241
VN - Vietnam 189
KR - Corea 142
HK - Hong Kong 134
BR - Brasile 88
NL - Olanda 83
DE - Germania 61
IN - India 52
FI - Finlandia 42
SE - Svezia 27
JP - Giappone 25
GB - Regno Unito 23
RU - Federazione Russa 23
SC - Seychelles 23
AT - Austria 18
FR - Francia 16
IE - Irlanda 16
AR - Argentina 15
CA - Canada 14
CH - Svizzera 13
MX - Messico 13
BG - Bulgaria 11
CI - Costa d'Avorio 11
PK - Pakistan 9
PL - Polonia 9
ID - Indonesia 8
BD - Bangladesh 5
CO - Colombia 5
EC - Ecuador 5
TG - Togo 5
TR - Turchia 5
ZA - Sudafrica 5
AL - Albania 3
ES - Italia 3
IL - Israele 3
LT - Lituania 3
MA - Marocco 3
MY - Malesia 3
NG - Nigeria 3
PY - Paraguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BE - Belgio 2
EG - Egitto 2
JO - Giordania 2
PE - Perù 2
TW - Taiwan 2
UA - Ucraina 2
UZ - Uzbekistan 2
AO - Angola 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BT - Bhutan 1
CL - Cile 1
CZ - Repubblica Ceca 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
LK - Sri Lanka 1
NC - Nuova Caledonia 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
Totale 3.422
Salva come PNG Salva come JPEG
Città #
Singapore 398
Hefei 329
Ashburn 188
Seoul 142
Hong Kong 129
Bologna 97
Santa Clara 69
Beijing 54
Ho Chi Minh City 54
Hanoi 50
Dallas 39
Bengaluru 33
Los Angeles 33
Boardman 31
Milan 26
Rome 25
Tokyo 25
Helsinki 24
New York 23
San Jose 19
Redondo Beach 17
Dublin 16
Lappeenranta 16
Buffalo 15
Tongling 14
Falkenstein 13
Nuremberg 13
São Paulo 13
Guangzhou 12
Abidjan 11
Amsterdam 11
Bern 11
Da Nang 11
Frankfurt am Main 11
Sofia 11
Munich 10
Florence 9
Orem 9
Vienna 9
Brooklyn 8
Chandler 8
Chicago 8
Lahore 8
Mexico City 8
Shanghai 8
Stockholm 8
Warsaw 8
Montreal 7
Boston 6
Denver 6
Haiphong 6
Jakarta 6
Houston 5
Johannesburg 5
Lomé 5
Shijiazhuang 5
Vũng Tàu 5
Ankara 4
Castel Maggiore 4
Chennai 4
Curitiba 4
Dongguan 4
Düsseldorf 4
Ha Long 4
Ninh Bình 4
Paris 4
Phoenix 4
Qingdao 4
Seattle 4
Shenyang 4
The Dalles 4
Thái Nguyên 4
Toronto 4
Atlanta 3
Biên Hòa 3
Borgo Tossignano 3
Cattolica 3
Changsha 3
Chongqing 3
Desio 3
Flero 3
Hyderabad 3
Liverpool 3
Ningbo 3
Princeton 3
Quito 3
Quận Một 3
Salt Lake City 3
Wuhan 3
Amman 2
Baku 2
Bexley 2
Brasília 2
Brussels 2
Buon Ma Thuot 2
Bắc Ninh 2
Cairo 2
Cambridge 2
Campalto 2
Can Tho 2
Totale 2.274
Salva come PNG Salva come JPEG
Nome #
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 169
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 146
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 142
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 136
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 128
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 126
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 126
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 126
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 120
TKIs in combination with immunotherapy for hepatocellular carcinoma 118
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 116
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 115
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 113
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease 111
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 106
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 105
Association between anatomic variations of extrahepatic and intrahepatic bile ducts: Do look up! 98
Advancements in immunotherapy for hepatocellular carcinoma 95
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 80
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 77
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 71
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement 68
RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives 62
Liver Fat Quantification: When do We Need It? 60
Letter to the editor on the article Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement by Zhou and collaborators 56
Perirenal ultrasound abnormality: When to think at Xantogranulomatous Erdheim-Chester disease 52
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 52
Thinking outside the box: unconventional artificial intelligence algorithms in the detection and management of liver cirrhosis 50
Ultrasound, the handyman serving our whole populations in the post COVID-19 pandemic 50
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? 49
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 46
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe 44
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis? 42
Artificial intelligence in Ultrasound: Pearls and pitfalls in 2024 37
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 34
Ultrasound in clinical enviroments: Where are we standing? 33
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 32
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 32
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 30
Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review 30
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 30
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 28
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma 27
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 24
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 22
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 22
Occupational toxicants in MASLD: Bias, complexity, and future directions 20
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 19
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 19
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma 18
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 18
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib 15
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab 3
Totale 3.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.365
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.365
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 0 0 1 7 2 0 2 4
2022/2023130 2 9 5 4 6 8 5 10 36 3 20 22
2023/2024166 10 14 12 11 12 30 7 28 10 12 12 8
2024/20251.104 24 78 76 73 102 46 103 32 47 106 122 295
2025/20262.132 375 444 284 375 434 167 53 0 0 0 0 0
Totale 3.548